<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04442906</url>
  </required_header>
  <id_info>
    <org_study_id>5355</org_study_id>
    <nct_id>NCT04442906</nct_id>
  </id_info>
  <brief_title>Analgesia After Knee Arthroscopy :Dexmedetomidine vs Fentanyl</brief_title>
  <official_title>Comparative Study Between Dexmedetomidine and Fentanyl as an Adjuvant to Intra-articular Bupivacaine for Postoperative Analgesia After Knee Arthroscopy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate analgesic effects Bupivacaine, Bupivacaine plus
      Dexmedetomidine and Bupivacaine plus Fentanyl in relieving pain after knee arthroscopic
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assuming that the mean and standard deviation of visual analogue scale (VAS) of
      dexmedetomidine group is 1.7 ± 0.86 versus fentanyl group is 2.6 ± 1.22 at confidence
      interval 95% and power 80%. So, the total sample size is 45 patients (15 in each group) using
      Open Epi program.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>analgesia for postoperative pain after knee arthroscopy: dexmedetomidine+bupivacaine, fentanyl+bupivacaine , bupivacaine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>anesthetist not sharing in the study will assess patient</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>pain intensity at rest (static)</measure>
    <time_frame>immediately postoperative 0 minute (admission to RECOVERY ROOM)</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity at rest(static)</measure>
    <time_frame>at 30 min postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity at rest (static)</measure>
    <time_frame>at 1 hour postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity at rest (static)</measure>
    <time_frame>at 2 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity at rest (static)</measure>
    <time_frame>at 4 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity at rest (static)</measure>
    <time_frame>at 6 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity at rest (static)</measure>
    <time_frame>at 8 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity at rest (static)</measure>
    <time_frame>at 12 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity at rest (static)</measure>
    <time_frame>at 24 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity on mobilization of operated knee (dynamic)</measure>
    <time_frame>immediately postoperative 0 minute (admission to RECOVERY ROOM)</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity on mobilization of operated knee (dynamic)</measure>
    <time_frame>at 30 min postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity on mobilization of operated knee (dynamic)</measure>
    <time_frame>at 1 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity on mobilization of operated knee (dynamic)</measure>
    <time_frame>at 2 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity on mobilization of operated knee (dynamic)</measure>
    <time_frame>at 4 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity on mobilization of operated knee (dynamic)</measure>
    <time_frame>at 6 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity on mobilization of operated knee (dynamic)</measure>
    <time_frame>at 8 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity on mobilization of operated knee (dynamic)</measure>
    <time_frame>at 12 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity on mobilization of operated knee (dynamic)</measure>
    <time_frame>at 24 hours postoperative</time_frame>
    <description>measured by VAS on 0-10 cm scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of analgesia</measure>
    <time_frame>within 24 hours postoperative</time_frame>
    <description>start from intra-articular injection of drug to the first request of analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total analgesic dose of ketorolac</measure>
    <time_frame>within 24 hours postoperative</time_frame>
    <description>total consumption of rescue analgesia (ketorolac) postoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total analgesic dose of pethidine</measure>
    <time_frame>within 24 hours postoperative</time_frame>
    <description>total consumption of rescue analgesia (pethidine) postoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects of studied drugs</measure>
    <time_frame>within 24 hours postoperative</time_frame>
    <description>adverse effects occur within 24 hours postoperative e.g. bradycardia, itching</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IGroup B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group BD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>. Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group BF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).</description>
    <arm_group_label>group BD</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug)</description>
    <arm_group_label>group BF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacain</intervention_name>
    <description>Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.</description>
    <arm_group_label>group B</arm_group_label>
    <arm_group_label>group BD</arm_group_label>
    <arm_group_label>group BF</arm_group_label>
    <other_name>marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  either sex, age 21-45 years, American Society of Anesthesia (ASA) I - II for elective
             knee arthroscopy.

        Exclusion Criteria:

          -  The patients with history of hepatic and renal diseases, psychiatric disorders,
             prolonged intake of (NSAIDS, opioids and tricyclic antidepressant), allergy to study
             drugs and patient who received analgesics up to 24 hr. before surgery were excluded
             from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina Salem, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>faculty of medicine , Zagazig University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dina Salem, MD.</last_name>
    <phone>01099333513</phone>
    <phone_ext>002</phone_ext>
    <email>dinamaghraby@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alshimaa Kamel, MD.</last_name>
    <phone>01005593169</phone>
    <phone_ext>002</phone_ext>
    <email>AlshimaaKamel80@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zagazig university</name>
      <address>
        <city>Zagazig</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Salem, MD.</last_name>
      <phone>01099333513</phone>
      <phone_ext>002</phone_ext>
      <email>dinamaghraby@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Alshimaa Kamel, MD</last_name>
      <phone>01005593169</phone>
      <phone_ext>002</phone_ext>
      <email>AlshimaaKamel80@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 20, 2020</last_update_submitted>
  <last_update_submitted_qc>June 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Dina Abdelhameed Elsadek Salem</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>fentanyl</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>knee arthroscopy</keyword>
  <keyword>postoperative analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

